Masanori Kawasaki

Structure–Activity Relationship Study of Antimalarial Asparagine-Derived Proteasome Inhibitors

Hao Zhang, Daqiang Li, Hao-Chi Hsu, Akshay Vishwanatha et autres

Abstract Malaria remains a significant global health threat, affecting millions of lives each year. The causative agents, Plasmodium parasites, are highly resilient and have developed resistance to nearly all existing antimalarial drugs. The Plasmodium 20S proteasome core (Pf20S), a central component of …

us, Ouganda (code pays fourni par la source)

Age-Stratified Effect of Rivaroxaban Monotherapy for Atrial Fibrillation in Stable Coronary Artery Disease

Junichi Yamaguchi, Hiroyuki Arashi, Nobuhisa Hagiwara, Satoshi Yasuda et autres

Importance: Antithrombotic therapy is crucial for older patients with coronary artery disease (CAD) and atrial fibrillation (AF) who are at a high risk of bleeding and thrombotic events. Objective: To examine the age-stratified effects of rivaroxaban monotherapy compared with those of rivaroxaban …

jp (code pays fourni par la source)

Quantification of bactericidal activity using the PATHFAST TB LAM Ag assay during the first 14 days of pulmonary tuberculosis treatment

Ayumi Akinaga, Andreas Henri Diacon, Remous Ocloo, Atsushi Yanagida et autres

Background: Tuberculosis (TB) remains a global health challenge. Culture-free, rapid, and quantitative biomarkers to monitor treatment response are critical to accelerate development of better TB treatments. The PATHFAST TB LAM Ag assay (PATHFAST-LAM), a desktop chemiluminescent enzyme immunoassay that measures mycobacterial lipoarabinomannan …

jp, Afrique du Sud, es, us (code pays fourni par la source)

Correction: Performance of novel antibodies for lipoarabinomannan to develop diagnostic tests for Mycobacterium tuberculosis

Jason L. Cantera, Lorraine M. Lillis, Roger B. Peck, Emmanuel Moreau et autres

[This corrects the article DOI: 10.1371/journal.pone.0274415.].

ca, tw (code pays fourni par la source)

Isolation and purification of lipoarabinomannan from urine of adults with active TB

Jason L. Cantera, Andrew Rashid, Lorraine M. Lillis, Roger B. Peck et autres

us, Afrique du Sud, jp, ch (code pays fourni par la source)

Performance of novel antibodies for lipoarabinomannan to develop diagnostic tests for Mycobacterium tuberculosis

Jason L. Cantera, Lorraine M. Lillis, Roger B. Peck, Emmanuel Moreau et autres

Lipoarabinomannan (LAM), a component of the Mycobacterium tuberculosis (MTB) cell wall, is detectable in the urine of MTB infected patients with active tuberculosis (TB). LAM-specific antibodies (Igs) have been developed by a variety of traditional and recombinant methods for potential use in …

us, ch, gb, Ouganda, jp, se (code pays fourni par la source)

Rivaroxaban Monotherapy vs Combination Therapy With Antiplatelets on Total Thrombotic and Bleeding Events in Atrial Fibrillation With Stable Coronary Artery Disease

Ryo Naito, Katsumi Miyauchi, Satoshi Yasuda, Koichi Kaikita et autres

Importance: Appropriate regimens of antithrombotic therapy for patients with atrial fibrillation (AF) and coronary artery disease (CAD) have not yet been established. Objective: To compare the total number of thrombotic and/or bleeding events between rivaroxaban monotherapy and combined rivaroxaban and antiplatelet therapy …

jp (code pays fourni par la source)

Performance of novel antibodies for lipoarabinomannan to develop diagnostic tests for Mycobacterium tuberculosis

Jason L. Cantera, Lorraine M. Lillis, Roger B. Peck, Emmanuel Moreau et autres

Abstract Lipoarabinomannan (LAM), a component of the Mycobacterium tuberculosis (MTB) cell wall, is detectable in the urine of MTB infected patients with active tuberculosis (TB). LAM-specific antibodies (Igs) have been developed by a variety of traditional and recombinant methods for potential use …

us, ch, gb, Ouganda, jp, se (code pays fourni par la source)

Rivaroxaban Monotherapy in Patients With Atrial Fibrillation After Coronary Stenting

Tetsuya Matoba, Satoshi Yasuda, Koichi Kaikita, Masaharu Akao et autres

jp (code pays fourni par la source)

Macrocyclic Peptides that Selectively Inhibit the Mycobacterium tuberculosis Proteasome

Hao Zhang, Hao-Chi Hsu, Shoshanna C. Kahne, Ryoma Hara et autres

Treatment of tuberculosis (TB) currently takes at least 6 months. Latent Mycobacterium tuberculosis (Mtb) is phenotypically tolerant to most anti-TB drugs. A key hypothesis is that drugs that kill nonreplicating (NR) Mtb may shorten treatment when used in combination with conventional drugs. …

us (code pays fourni par la source)

Isolation and Purification of Lipoarabinomannan from Urine of Adults with Active Tuberculosis

Jason L. Cantera, Andrew Rashid, Lorraine L. Lillis, Roger B. Peck et autres

Abstract Lipoarabinomannan (LAM) is a cell wall component of Mycobacterium tuberculosis that is excreted in the urine of persons with active tuberculosis (TB). Limited diagnostic sensitivity of LAM immunoassays has been due to selecting antibodies against LAM derived from in vitro cultured …

us, jp, ch (code pays fourni par la source)

Adduct Formation of Delamanid with NAD in Mycobacteria

Mikayo Hayashi, Akihito Nishiyama, Ryuki Kitamoto, Yoshitaka Tateishi et autres

Delamanid (DLM), a nitro-dihydroimidazooxazole derivative currently approved for pulmonary multidrug-resistant tuberculosis (TB) therapy, is a prodrug activated by mycobacterial 7,8-didemethyl-8-hydroxy 5-deazaflavin electron transfer coenzyme (F 420 )-dependent nitroreductase (Ddn). Despite inhibiting the biosynthesis of a subclass of mycolic acids, the active DLM …

jp, id (code pays fourni par la source)